Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings

Zacks Zacks
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings

Alnylam Pharmaceuticals (ALNY) reported $1.1 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 84.9%. EPS of $1.25 for the same period compares to $0.06 a year ago.

The reported revenue represents a surprise of -3.35% over the Zacks Consensus Estimate of $1.14 billion. With the consensus EPS estimate being $1.16, the EPS surprise was +8.16%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Product Revenue- Onpattro- United States: $12.02 million versus $5.37 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -39.7% change. Net Product Revenue- Oxlumo- United States: $17.61 million versus $23.94 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.1% change. Net Product Revenue- Givlaari- United States: $56.34 million compared to the $47.24 million average estimate based on two analysts. The reported number represents a change of +25.1% year over year. Net Product Revenue- Amvuttra- United States: $641.57 million versus the two-analyst average estimate of $619.86 million. The reported number represents a year-over-year change of +250.1%. Revenues- Product revenues, net: $994.72 million versus $1.01 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +120.6% change. Net Product Revenue- Givlaari: $86.8 million versus the six-analyst average estimate of $79.72 million. The reported number represents a year-over-year change of +34.3%. Revenues- Net revenues from research collaborators: $40.94 million compared to the $94.22 million average estimate based on six analysts. The reported number represents a change of -61.7% year over year. Net Product Revenue- Total Rare: $136.44 million compared to the $134.95 million average estimate based on six analysts. Net Product Revenue- Oxlumo: $49.65 million versus the six-analyst average estimate of $55.23 million. The reported number represents a year-over-year change of +13.9%. Revenues- Royalty revenue: $61.37 million versus $55.64 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +73.4% change. Net Product Revenue- Onpattro: $31.69 million compared to the $39.82 million average estimate based on five analysts. The reported number represents a change of -43.5% year over year. Net Product Revenue- Amvuttra: $826.59 million compared to the $837.17 million average estimate based on five analysts. The reported number represents a change of +188.5% year over year.

View all Key Company Metrics for Alnylam here>>>

Shares of Alnylam have returned -12.2% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include

Stock #1: A Disruptive Force with Notable Growth and Resilience

Stock #2: Bullish Signs Signaling to Buy the Dip

Stock #3: One of the Most Compelling Investments in the Market

Stock #4: Leader In a Red-Hot Industry Poised for Growth

Stock #5: Modern Omni-Channel Platform Coiled to Spring

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.

See Our Newest 5 Stocks Set to Double Picks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Other news